{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T05:13:50Z","timestamp":1783401230466,"version":"3.54.6"},"reference-count":64,"publisher":"MDPI AG","issue":"13","license":[{"start":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T00:00:00Z","timestamp":1782777600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Tacrolimus is an immunosuppressant drug commonly used in transplantation. Although multiple studies have demonstrated that polymorphisms in the CYP3A5 gene impact the metabolism of tacrolimus, routine pre-transplant testing for these markers is still not broadly implemented. TacroType\u2122\u2014a new laboratory-developed test implemented by One Lambda Laboratories\u2014utilizes a qPCR-based six-plex assay for CYP3A5 genotyping and detects the three most common genetic variants (*3, *6 and *7) associated with loss of CYP3A5 protein function and reduced tacrolimus metabolism. TacroType was optimized to address known sources of protocol, technical or sample variability to achieve accurate and reproducible genotyping results. An analytical performance study was completed following CLSI guidelines. Accuracy was confirmed for each possible CYP3A5 genotype involving six target alleles using 32 well-characterized reference samples. TacroType exhibited accurate performance within a broad range of DNA concentrations and quality. Precision studies indicated consistent genotyping results across four operators, two instrument types and five lots of reagents. Accurate and reproducible assay performance was demonstrated using whole blood from 95 donors and buccal swabs from 65 donors. The analytical performance of TacroType was evaluated in 4014 total qPCR reactions, with a report rate of 99.8% and genotyping accuracy of 100% (95% confidence interval of 99.9%).<\/jats:p>","DOI":"10.3390\/ijms27135917","type":"journal-article","created":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:50:37Z","timestamp":1782867037000},"page":"5917","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["A Novel Laboratory-Developed Test Using Multiplex qPCR to Further Personalize Tacrolimus Dosing"],"prefix":"10.3390","volume":"27","author":[{"given":"Abhishek","family":"Chadha","sequence":"first","affiliation":[{"name":"One Lambda Inc., Part of Thermo Fisher Scientific Inc.\u00a9, West Hills, CA 91304, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-1973-9600","authenticated-orcid":false,"given":"Zhiwei","family":"Wang","sequence":"additional","affiliation":[{"name":"One Lambda Inc., Part of Thermo Fisher Scientific Inc.\u00a9, West Hills, CA 91304, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-4863-0185","authenticated-orcid":false,"given":"Max","family":"Mamroth","sequence":"additional","affiliation":[{"name":"One Lambda Inc., Part of Thermo Fisher Scientific Inc.\u00a9, West Hills, CA 91304, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Hunter","sequence":"additional","affiliation":[{"name":"One Lambda Laboratories, Part of Thermo Fisher Scientific Inc., West Hills, CA 91304, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lin","family":"Xu","sequence":"additional","affiliation":[{"name":"One Lambda Laboratories, Part of Thermo Fisher Scientific Inc., West Hills, CA 91304, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanghamitra","family":"Sahoo","sequence":"additional","affiliation":[{"name":"One Lambda Laboratories, Part of Thermo Fisher Scientific Inc., West Hills, CA 91304, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Rumpler","sequence":"additional","affiliation":[{"name":"One Lambda Laboratories, Part of Thermo Fisher Scientific Inc., West Hills, CA 91304, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandre","family":"Vlassov","sequence":"additional","affiliation":[{"name":"One Lambda Inc., Part of Thermo Fisher Scientific Inc.\u00a9, West Hills, CA 91304, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-2369-073X","authenticated-orcid":false,"given":"Anna K.","family":"Chikova","sequence":"additional","affiliation":[{"name":"One Lambda Inc., Part of Thermo Fisher Scientific Inc.\u00a9, West Hills, CA 91304, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,6,30]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"S22","DOI":"10.1016\/j.ajt.2025.01.020","article-title":"OPTN\/SRTR 2023 Annual Data Report: Kidney","volume":"25","author":"Lentine","year":"2025","journal-title":"Am. J. Transplant."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"S138","DOI":"10.1016\/j.ajt.2025.01.021","article-title":"OPTN\/SRTR 2023 Annual Data Report: Pancreas","volume":"25","author":"Kandaswamy","year":"2025","journal-title":"Am. J. Transplant."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"S193","DOI":"10.1016\/j.ajt.2025.01.022","article-title":"OPTN\/SRTR 2023 Annual Data Report: Liver","volume":"25","author":"Kwong","year":"2025","journal-title":"Am. J. Transplant."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"S288","DOI":"10.1016\/j.ajt.2025.01.023","article-title":"OPTN\/SRTR 2023 Annual Data Report: Intestine","volume":"25","author":"Horslen","year":"2025","journal-title":"Am. J. Transplant."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"S329","DOI":"10.1016\/j.ajt.2025.01.024","article-title":"OPTN\/SRTR 2023 Annual Data Report: Heart","volume":"25","author":"Colvin","year":"2025","journal-title":"Am. J. Transplant."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1080\/10428194.2023.2300708","article-title":"Outcomes with HLA-Matched Unrelated Donor versus Haploidentical Hematopoietic Cell Transplantation","volume":"65","author":"Mushtaq","year":"2024","journal-title":"Leuk. Lymphoma"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"S422","DOI":"10.1016\/j.ajt.2025.01.025","article-title":"OPTN\/SRTR 2023 Annual Data Report: Lung","volume":"25","author":"Valapour","year":"2025","journal-title":"Am. J. Transplant."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1097\/FPC.0b013e328364db84","article-title":"PharmGKB Summary: Cyclosporine and Tacrolimus Pathways","volume":"23","author":"Barbarino","year":"2013","journal-title":"Pharmacogenet Genom."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1097\/00007691-199512000-00007","article-title":"Mode of Action of Tacrolimus (FK506): Molecular and Cellular Mechanisms","volume":"17","author":"Thomson","year":"1995","journal-title":"Ther. Drug Monit."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1002\/phar.2653","article-title":"Tacrolimus Time in Therapeutic Range and Long-Term Outcomes in Heart Transplant Recipients","volume":"42","author":"Adie","year":"2022","journal-title":"Pharmacotherapy"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1002\/phar.2601","article-title":"Impact of CYP3A5 Phenotype on Tacrolimus Time in Therapeutic Range and Clinical Outcomes in Pediatric Renal and Heart Transplant Recipients","volume":"41","author":"Leino","year":"2021","journal-title":"Pharmacotherapy"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1002\/cpt.1629","article-title":"Early Tacrolimus Concentrations After Lung Transplant Are Predicted by Combined Clinical and Genetic Factors and Associated with Acute Kidney Injury","volume":"107","author":"Miano","year":"2020","journal-title":"Clin. Pharmacol. Ther."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1097\/FTD.0000000000000640","article-title":"Therapeutic Drug Monitoring of Tacrolimus-Personalized Therapy: Second Consensus Report","volume":"41","author":"Brunet","year":"2019","journal-title":"Ther. Drug Monit."},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Thongprayoon, C., Hansrivijit, P., Kovvuru, K., Kanduri, S.R., Bathini, T., Pivovarova, A., Smith, J.R., and Cheungpasitporn, W. (2020). Impacts of High Intra- and Inter-Individual Variability in Tacrolimus Pharmacokinetics and Fast Tacrolimus Metabolism on Outcomes of Solid Organ Transplant Recipients. J. Clin. Med., 9.","DOI":"10.3390\/jcm9072193"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1097\/FPC.0b013e328351d47f","article-title":"PharmGKB Summary: Very Important Pharmacogene Information for CYP3A5","volume":"22","author":"Lamba","year":"2012","journal-title":"Pharmacogenet Genom."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1097\/FTD.0b013e3181f3c063","article-title":"A Systematic Review of the Effect of CYP3A5 Genotype on the Apparent Oral Clearance of Tacrolimus in Renal Transplant Recipients","volume":"32","author":"Barry","year":"2010","journal-title":"Ther. Drug Monit."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1007\/s40262-016-0390-7","article-title":"The Effect of Weight and CYP3A5 Genotype on the Population Pharmacokinetics of Tacrolimus in Stable Paediatric Renal Transplant Recipients","volume":"55","author":"Cransberg","year":"2016","journal-title":"Clin. Pharmacokinet."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1038\/clpt.2012.175","article-title":"Measurement and Compartmental Modeling of the Effect of CYP3A5 Gene Variation on Systemic and Intrarenal Tacrolimus Disposition","volume":"92","author":"Zheng","year":"2012","journal-title":"Clin. Pharmacol. Ther."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1007\/s13318-018-0478-6","article-title":"Impact of the CYP3A5*1 Allele on the Pharmacokinetics of Tacrolimus in Japanese Heart Transplant Patients","volume":"43","author":"Uno","year":"2018","journal-title":"Eur. J. Drug Metab. Pharmacokinet."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1111\/bcpt.13138","article-title":"Dosing Recommendations Based on Population Pharmacokinetics of Tacrolimus in Mexican Adult Patients with Kidney Transplant","volume":"124","year":"2019","journal-title":"Basic Clin. Pharmacol. Toxicol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.2217\/pgs.13.133","article-title":"Impact of CYP3A5 Genotype on Tacrolimus versus Midazolam Clearance in Renal Transplant Recipients: New Insights in CYP3A5-Mediated Drug Metabolism","volume":"14","author":"Verbeke","year":"2013","journal-title":"Pharmacogenomics"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1007\/s00228-015-1963-3","article-title":"Population Pharmacokinetics and Pharmacogenetics of Once Daily Tacrolimus Formulation in Stable Liver Transplant Recipients","volume":"72","author":"Moes","year":"2016","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"Cui, Y.-F., Pan, Y., Zhu, M.-F., and Jiao, Z. (2023). Pharmacokinetic Evaluation of Tacrolimus in Chinese Adult Patients during the Early Stages Post-Lung Transplantation. J. Pers. Med., 13.","DOI":"10.3390\/jpm13040656"},{"key":"ref_24","doi-asserted-by":"crossref","unstructured":"Pei, L., Li, R., Zhou, H., Du, W., Gu, Y., Jiang, Y., Wang, Y., Chen, X., Sun, J., and Zhu, J. (2023). A Physiologically Based Pharmacokinetic Approach to Recommend an Individual Dose of Tacrolimus in Adult Heart Transplant Recipients. Pharmaceutics, 15.","DOI":"10.3390\/pharmaceutics15112580"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1007\/s00228-014-1785-8","article-title":"Association between Interleukin-18 Promoter Variants and Tacrolimus Pharmacokinetics in Chinese Renal Transplant Patients","volume":"71","author":"Xing","year":"2015","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"Seligson, N.D., Zhang, X., Zemanek, M.C., Johnson, J.A., VanGundy, Z., Wang, D., Phelps, M.A., Roddy, J., Hofmeister, C.C., and Li, J. (2023). CYP3A5 Influences Oral Tacrolimus Pharmacokinetics and Timing of Acute Kidney Injury Following Allogeneic Hematopoietic Stem Cell Transplantation. Front. Pharmacol., 14.","DOI":"10.3389\/fphar.2023.1334440"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/j.clpt.2006.06.008","article-title":"Population Pharmacokinetic and Pharmacogenomic Analysis of Tacrolimus in Pediatric Living-Donor Liver Transplant Recipients","volume":"80","author":"Fukudo","year":"2006","journal-title":"Clin. Pharmacol. Ther."},{"key":"ref_28","unstructured":"FDA (2025, November 04). Table of Pharmacogenetic Associations, Available online: https:\/\/www.fda.gov\/medical-devices\/precision-medicine\/table-pharmacogenetic-associations."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1002\/cpt.113","article-title":"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for CYP3A5 Genotype and Tacrolimus Dosing","volume":"98","author":"Birdwell","year":"2015","journal-title":"Clin. Pharmacol. Ther."},{"key":"ref_30","unstructured":"(2025, November 04). Annotation of DPWG Guideline for Tacrolimus and CYP3A5. Available online: https:\/\/www.clinpgx.org\/guidelineAnnotation\/PA166104983."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1016\/j.jmoldx.2023.06.008","article-title":"CYP3A4 and CYP3A5 Genotyping Recommendations: A Joint Consensus Recommendation of the Association for Molecular Pathology, Clinical Pharmacogenetics Implementation Consortium, College of American Pathologists, Dutch Pharmacogenetics Working Group of the Royal Dutch Pharmacists Association, European Society for Pharmacogenomics and Personalized Therapy, and Pharmacogenomics Knowledgebase","volume":"25","author":"Pratt","year":"2023","journal-title":"J. Mol. Diagn."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1016\/j.kint.2023.06.021","article-title":"A Prospective Controlled, Randomized Clinical Trial of Kidney Transplant Recipients Developed Personalized Tacrolimus Dosing Using Model-Based Bayesian Prediction","volume":"104","author":"Lloberas","year":"2023","journal-title":"Kidney Int."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1964","DOI":"10.1111\/bcp.13980","article-title":"Therapeutic Concentration Achievement and Allograft Survival Comparing Usage of Conventional Tacrolimus Doses and CYP3A5 Genotype-Guided Doses in Renal Transplantation Patients","volume":"85","author":"Anutrakulchai","year":"2019","journal-title":"Br. J. Clin. Pharmacol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1002\/cpt.2163","article-title":"Avoiding Tacrolimus Underexposure and Overexposure with a Dosing Algorithm for Renal Transplant Recipients: A Single Arm Prospective Intervention Trial","volume":"110","author":"Francke","year":"2021","journal-title":"Clin. Pharmacol. Ther."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"e13285","DOI":"10.1111\/petr.13285","article-title":"A Randomized Clinical Trial of Age and Genotype-Guided Tacrolimus Dosing after Pediatric Solid Organ Transplantation","volume":"22","author":"Min","year":"2018","journal-title":"Pediatr. Transplant."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"2085","DOI":"10.1111\/ajt.13691","article-title":"A Randomized Controlled Trial Comparing the Efficacy of Cyp3a5 Genotype-Based With Body-Weight-Based Tacrolimus Dosing After Living Donor Kidney Transplantation","volume":"16","author":"Shuker","year":"2016","journal-title":"Am. J. Transplant."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1097\/00007890-199802270-00011","article-title":"Racial Differences in Renal Transplantation after Immunosuppression with Tacrolimus versus Cyclosporine. FK506 Kidney Transplant Study Group","volume":"65","author":"Neylan","year":"1998","journal-title":"Transplantation"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"e1379","DOI":"10.1097\/TXD.0000000000001379","article-title":"Impact of CYP3A5 Status on the Clinical and Financial Outcomes Among African American Kidney Transplant Recipients","volume":"8","author":"Obayemi","year":"2022","journal-title":"Transplant. Direct"},{"key":"ref_39","doi-asserted-by":"crossref","unstructured":"Thomas, E.C., Randall, D.W., Khurram, M.A., and Yaqoob, M.M. (2025). Ethnic Differences in Early Blood Tacrolimus Concentrations after Kidney Transplantation: A Retrospective Observational Study. BMC Nephrol., 26.","DOI":"10.1186\/s12882-025-04326-6"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1002\/phar.1591","article-title":"African-American Race Modifies the Influence of Tacrolimus Concentrations on Acute Rejection and Toxicity in Kidney Transplant Recipients","volume":"35","author":"Taber","year":"2015","journal-title":"Pharmacotherapy"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"e14893","DOI":"10.1111\/ctr.14893","article-title":"Higher Number of Tacrolimus Dose Adjustments in Kidney Transplant Recipients Who Are Extensive and Intermediate CYP3A5 Metabolizers","volume":"37","author":"Reininger","year":"2023","journal-title":"Clin. Transplant."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"240","DOI":"10.4103\/ijn.IJN_278_20","article-title":"Efficacy and Outcomes of CYP3A5 Genotype-Based Tacrolimus Dosing Compared to Conventional Body Weight-Based Dosing in Living Donor Kidney Transplant Recipients","volume":"32","author":"Raj","year":"2022","journal-title":"Indian J. Nephrol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"e70363","DOI":"10.1111\/ctr.70363","article-title":"Improved LCP Tacrolimus XR Dosing and Monitoring Outcomes with a Genotype-Based Dosing Algorithm Versus Weight Based Dosing","volume":"39","author":"Wolesensky","year":"2025","journal-title":"Clin. Transplant."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1097\/FPC.0000000000000549","article-title":"CYP3A5 Pharmacogenetic Testing for Tacrolimus in Pediatric Heart Transplant Patients: A Budget Impact Analysis","volume":"35","author":"Wang","year":"2025","journal-title":"Pharmacogenet. Genom."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1007\/s40262-025-01529-w","article-title":"A Tacrolimus Population Pharmacokinetic Model for Adult Allogeneic Hematopoietic Cell Transplant Recipients Provides Clinical Opportunities for Precision Dosing","volume":"64","author":"Dunlap","year":"2025","journal-title":"Clin. Pharmacokinet."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1038\/s41397-024-00330-5","article-title":"Cost-Utility Analysis of Pharmacogenomics-Guided Tacrolimus Treatment in Austrian Kidney Transplant Recipients Participating in the U-PGx PREPARE Study","volume":"24","author":"Fragoulakis","year":"2024","journal-title":"Pharmacogenom. J."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"e134","DOI":"10.1093\/ajhp\/zxaf215","article-title":"Establishing a CYP3A5 Genotype-Guided Tacrolimus Dosing Protocol in Adult Kidney Transplant Recipients","volume":"83","author":"Pasternak","year":"2026","journal-title":"Am. J. Health Syst. Pharm."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1002\/cpt.2563","article-title":"PharmVar GeneFocus: CYP3A5","volume":"112","author":"Savieo","year":"2022","journal-title":"Clin. Pharmacol. Ther."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1002\/cpt.2321","article-title":"Pharmacogene Variation Consortium: A Global Resource and Repository for Pharmacogene Variation","volume":"110","author":"Gaedigk","year":"2021","journal-title":"Clin. Pharmacol. Ther."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1002\/cpt.690","article-title":"Worldwide Distribution of Cytochrome P450 Alleles: A Meta-Analysis of Population-Scale Sequencing Projects","volume":"102","author":"Zhou","year":"2017","journal-title":"Clin. Pharmacol. Ther."},{"key":"ref_51","unstructured":"(2025, January 29). PROGRAF (Tacrolimus) [Package Insert], Available online: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2020\/050708s052,050709s044,210115s004lbl.Pdf."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1067\/mcp.2001.113183","article-title":"The Pharmacokinetics and Metabolic Disposition of Tacrolimus: A Comparison across Ethnic Groups","volume":"69","author":"Mancinelli","year":"2001","journal-title":"Clin. Pharmacol. Ther."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1016\/S0041-1345(98)00275-9","article-title":"Demographic Considerations in Tacrolimus Pharmacokinetics","volume":"30","author":"Fitzsimmons","year":"1998","journal-title":"Transplant. Proc."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1002\/jcph.2249","article-title":"Implementation of Clinical Cytochrome P450 3A Genotyping for Tacrolimus Dosing in a Large Kidney Transplant Program","volume":"63","author":"Tillman","year":"2023","journal-title":"J. Clin. Pharmacol."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1097\/01.tp.0000173379.53347.31","article-title":"Race\/Ethnicity, Poverty Status, and Renal Transplant Outcomes","volume":"80","author":"Press","year":"2005","journal-title":"Transplantation"},{"key":"ref_56","doi-asserted-by":"crossref","unstructured":"Bustin, S.A., van den Hoff, M.J.B., Pfaffl, M.W., Kubista, M., and Ruijter, J.M. (2026). Quantification Revisited: What qPCR Efficiency Models Reveal About Data Analysis Integrity. Int. J. Mol. Sci., 27.","DOI":"10.3390\/ijms27052337"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1007\/978-1-61737-954-3_6","article-title":"Targeted SNP Genotyping Using the TaqMan\u00ae Assay","volume":"700","author":"Schleinitz","year":"2011","journal-title":"Methods Mol. Biol."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1093\/clinchem\/hvaf043","article-title":"MIQE 2.0: Revision of the Minimum Information for Publication of Quantitative Real-Time PCR Experiments Guidelines","volume":"71","author":"Bustin","year":"2025","journal-title":"Clin. Chem."},{"key":"ref_59","unstructured":"Miller, S. (2018). CLSI MM17: Validation and Verification of Multiplex Nucleic Acid Assays, Clinical and Laboratory Standards Institute. [2nd ed.]."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"D948","DOI":"10.1093\/nar\/gkae1071","article-title":"Ensembl 2025","volume":"53","author":"Dyer","year":"2025","journal-title":"Nucleic Acids Res."},{"key":"ref_61","doi-asserted-by":"crossref","unstructured":"Tron, C., Woillard, J.-B., Houssel-Debry, P., David, V., Jezequel, C., Rayar, M., Balakirouchenane, D., Blanchet, B., Debord, J., and Petitcollin, A. (2020). Pharmacogenetic-Whole Blood and Intracellular Pharmacokinetic-Pharmacodynamic (PG-PK2-PD) Relationship of Tacrolimus in Liver Transplant Recipients. PLoS ONE, 15.","DOI":"10.1371\/journal.pone.0230195"},{"key":"ref_62","unstructured":"Toledo, A. (2026, June 08). Study of Pharmacogenomic-Guided Tacrolimus Dosing and Monitoring in Kidney Transplant Recipients (TAC3A5), Available online: https:\/\/clinicaltrials.gov\/study\/NCT03020589."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1038\/nature15393","article-title":"A Global Reference for Human Genetic Variation","volume":"526","author":"Auton","year":"2015","journal-title":"Nature"},{"key":"ref_64","unstructured":"Przygodzki, R. (2025). CLSI MM19: Establishing Molecular Testing in Medical Laboratory Environments, Clinical and Laboratory Standards Institute. [2nd ed.]."}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/27\/13\/5917\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T04:15:39Z","timestamp":1783397739000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/27\/13\/5917"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,30]]},"references-count":64,"journal-issue":{"issue":"13","published-online":{"date-parts":[[2026,7]]}},"alternative-id":["ijms27135917"],"URL":"https:\/\/doi.org\/10.3390\/ijms27135917","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,30]]}}}